Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Xeomin for upper limb spasticity in progressive multiple sclerosis and other chronic inflammatory CNS diseases
2007-006268-32Phase 2Completed
- Sponsor
- IRCCS Ospedale San Raffaele
- Start
- Nov 2007
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of botulinum toxin type A in multiple sclerosis (MS) and chronic inflammatory demyelinating polyneuropathy (CIDP), sponsored by IRCCS Ospedale San Raffaele. Primary endpoint: Efficacy and safety of one treatment with botulinum toxin type A. Started Nov 2007; status: completed.
02
Drugs
botulinum toxin type A
03
Conditions
multiple sclerosis (MS)chronic inflammatory demyelinating polyneuropathy (CIDP)
Beyond the preview
Go deeper on 2007-006268-32.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-006268-32.